SCHEMBL14746181

SCHEMBL14746181

COC(=O)c1c(O)c2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1cc3cc(CO)n(C)c3cc1CCC2

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 4/20 0.37
ALDH1A1 P00352 3/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
TSHR P16473 2/20 0.35
EDNRB P24530 1/20 0.34
SMURF2 Q9HAU4 2/20 0.33
SMURF1 Q9HCE7 2/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
POLB P06746 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
F2 P00734 1/20 0.33
LMNA P02545 1/20 0.33
MTNR1A P48039 1/20 0.33
MTNR1B P49286 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745710 0.98 EGLN1 (0.37) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL14746097 0.95 EGLN1 (0.38) EGLN1ALDH1A1MAPTTSHREDNRB
SCHEMBL16429014 0.93 EDNRB (0.39) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL14746160 0.92 EDNRB (0.39) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL14746196 0.89 EDNRB (0.40) EGLN1ALDH1A1TSHREDNRBSMN1; SMN2
SCHEMBL14745781 0.88 EGLN1 (0.35) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL14746001 0.87 EDNRB (0.39) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL16429204 0.87 EGLN1 (0.35) EGLN1ALDH1A1MAPTHPGDHSD17B10
SCHEMBL16429056 0.87 EGLN1 (0.36) EGLN1ALDH1A1MAPTHPGDTSHR
SCHEMBL14745679 0.86 GABRG2 (0.37) EGLN1ALDH1A1MAPTHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
WO-2016025932-A1 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP EGLN1 712/4885ALDH1A1 3792/4885MAPT 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.